“As we have continued to prioritize our TULSA-PRO® commercial activities in
Summary Third Quarter 2023 Results
For the quarter ended
Total operating expenses, which consist of research and development (“R&D”), general and administrative (“G&A”), and selling and distribution (“S&D”) expenses, were approximately
Expenditures for R&D for the three months ended
G&A expenses for the 2023 third quarter decreased by 15% to approximately
Third quarter 2023 S&D expenses were approximately
Net finance income for the three months ended
Third quarter 2023 net loss was approximately
Liquidity and Outstanding Share Capital
As at
As at
For complete financial results, please see Profound’s filings at www.sedarplus.ca, www.sec.gov and on the Company’s website at www.profoundmedical.com under “Financial” in the Investors section.
Conference Call Details
To participate in the conference call by telephone, please pre-register via this link to receive the dial-in number and your unique PIN.
The call will also be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.
About
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO® has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (“BPH”). TULSA-PRO® is CE marked,
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the
Forward-Looking Statements
This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound’s technology in the treatment of prostate cancer, BPH, uterine fibroids, palliative pain treatment and osteoid osteoma. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, regulatory approvals, reimbursement, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. In addition, there is uncertainty about the spread of the COVID-19 virus and the impact it will have on Profound’s operations, the demand for its products, global supply chains and economic activity in general. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.
For further information, please contact:
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
Interim Condensed Consolidated Balance Sheets
(Unaudited)
2023 $ | 2022 $ | |||||
Assets | ||||||
Current assets | ||||||
Cash | 33,625 | 46,517 | ||||
Trade and other receivables | 6,619 | 6,344 | ||||
Inventory | 7,425 | 7,941 | ||||
Prepaid expenses and deposits | 648 | 1,222 | ||||
Total current assets | 48,317 | 62,024 | ||||
Property and equipment | 940 | 899 | ||||
Intangible assets | 530 | 680 | ||||
Right-of-use assets | 657 | 818 | ||||
Total assets | 50,444 | 64,421 | ||||
Liabilities | ||||||
Current liabilities | ||||||
Accounts payable and accrued liabilities | 2,016 | 2,091 | ||||
Deferred revenue | 673 | 471 | ||||
Long-term debt | 1,905 | 523 | ||||
Derivative financial instrument | - | 563 | ||||
Lease liabilities | 250 | 239 | ||||
Income taxes payable | 343 | 298 | ||||
Total current liabilities | 5,187 | 4,185 | ||||
Long-term debt | 5,341 | 6,651 | ||||
Deferred revenue | 727 | 764 | ||||
Lease liabilities | 629 | 817 | ||||
Total liabilities | 11,884 | 12,417 | ||||
Shareholders’ Equity | ||||||
Share capital | 212,608 | 205,825 | ||||
Contributed surplus | 18,386 | 18,704 | ||||
Accumulated other comprehensive income | 16,588 | 16,837 | ||||
Deficit | (209,022 | ) | (189,362 | ) | ||
Total Shareholders’ Equity | 38,560 | 52,004 | ||||
Total Liabilities and Shareholders’ Equity | 50,444 | 64,421 |
Interim Condensed Consolidated Statements of Loss and Comprehensive Loss
(Unaudited)
Three months ended 2023 $ | Three months ended 2022 $ | Nine months ended 2023 $ | Nine months ended 2022 $ | |||||
Revenue | ||||||||
Recurring - non-capital | 1,728 | 1,235 | 4,797 | 3,420 | ||||
Capital equipment | - | 800 | 393 | 2,004 | ||||
1,728 | 2,035 | 5,190 | 5,424 | |||||
Cost of sales | 668 | 945 | 1,867 | 2,962 | ||||
Gross profit | 1,060 | 1,090 | 3,323 | 2,462 | ||||
Operating expenses | ||||||||
Research and development | 3,415 | 4,733 | 10,410 | 11,601 | ||||
General and administrative | 2,024 | 2,393 | 6,210 | 7,371 | ||||
Selling and distribution | 2,181 | 2,198 | 6,537 | 6,794 | ||||
Total operating expenses | 7,620 | 9,324 | 23,157 | 25,766 | ||||
Operating loss | 6,560 | 8,234 | 19,834 | 23,304 | ||||
Net finance income | (1,014 | ) | (3,271 | ) | (275 | ) | (4,243 | ) |
Loss before taxes | 5,546 | 4,963 | 19,559 | 19,061 | ||||
Income taxes | 18 | 34 | 101 | 81 | ||||
Net loss attributed to shareholders for the period | 5,564 | 4,997 | 19,660 | 19,142 | ||||
Other comprehensive (income) loss | ||||||||
Item that may be reclassified to loss | ||||||||
Foreign currency translation adjustment- net of tax | (3,915 | ) | 11,103 | 249 | 14,992 | |||
Net loss and comprehensive loss/(income) for the period | 1,649 | (6,106 | ) | 19,909 | 4,150 | |||
Loss per share | ||||||||
Basic and diluted loss per common share | 0.26 | 0.24 | 0.93 | 0.92 |
Interim Condensed Consolidated Statements of Cash Flows
(Unaudited)
Nine months ended 2023 $ | Nine months ended 2022 $ | |||
Operating activities | ||||
Net loss for the period | (19,660 | ) | (19,142 | ) |
Adjustments to reconcile net loss to net cash flows from operating activities: | ||||
Depreciation of property and equipment | 532 | 520 | ||
Amortization of intangible assets | 152 | 654 | ||
Depreciation of right-of-use assets | 163 | 174 | ||
Share-based compensation | 2,510 | 3,673 | ||
Interest and accretion expense | 582 | 46 | ||
Deferred revenue | 163 | 13 | ||
Change in fair value of derivative financial instrument | 232 | (145 | ) | |
Interest income on trade and other receivables | (119 | ) | (251 | ) |
Changes in non-cash working capital balances | ||||
Trade and other receivables | (155 | ) | (1,235 | ) |
Prepaid expenses and deposits | 574 | 654 | ||
Inventory | (54 | ) | (1,294 | ) |
Accounts payable and accrued liabilities | 165 | (501 | ) | |
Income taxes payable | 45 | - | ||
Foreign exchange on cash | (410 | ) | (2,348 | ) |
Net cash flow used in operating activities | (15,280 | ) | (19,182 | ) |
Financing activities | ||||
Payment of long-term debt interest | (489 | ) | - | |
Proceeds from share options exercised | 241 | 263 | ||
Proceeds from warrants exercised | 2,423 | - | ||
Payment of lease liabilities | (220 | ) | (240 | ) |
Total cash from financing activities | 1,955 | 23 | ||
Net change in cash during the period | (13,325 | ) | (19,159 | ) |
Foreign exchange on cash | 433 | (1,785 | ) | |
Cash – Beginning of period | 46,517 | 67,152 | ||
Cash – End of period | 33,625 | 46,208 |
Source:
2023 GlobeNewswire, Inc., source